Intersect ENT

OverviewSuggest Edit

Intersect ENT is an ear, nose, and throat medical technology company. It offers steroid releasing implants that are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. These products include the PROPEL family of products and the SINUVA sinus implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers, with applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician-administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.

TypePublic
Founded2003
HQMenlo Park, CA, US
Websiteintersectent.com
Employee Ratings3.2
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2020)406
Job Openings29
Revenue (FY, 2020)$80.6 M(-26%)
Share Price (May 2022)$28.2
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Intersect ENT

Thomas A. West

Thomas A. West

President and Chief Executive Officer, Director
Patrick Broderick

Patrick Broderick

Executive Vice President, General Counsel and Corporate Secretary
Reyna Fernandez

Reyna Fernandez

Chief Human Resources Officer
Rich Kaufman

Rich Kaufman

Chief Operating Officer & Senior Vice President R&D
Christine Kowalski

Christine Kowalski

Executive Vice President & Chief Operating Officer
Randy Meier

Randy Meier

Executive Vice President & Chief Financial Officer
Show more

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, CA, US (HQ)
1555 Adams Dr
Show all (1)

Intersect ENT Financials and Metrics

Intersect ENT Revenue

Embed Graph
View revenue for all periods
Intersect ENT's revenue was reported to be $80.55 m in FY, 2020 which is a 26.2% decrease from the previous period.
USD

Revenue (Q2, 2021)

27.3m

Gross profit (Q2, 2021)

19.0m

Gross profit margin (Q2, 2021), %

69.5%

Net income (Q2, 2021)

(16.6m)

EBIT (Q2, 2021)

(16.1m)

Market capitalization (13-May-2022)

945.0m

Closing stock price (13-May-2022)

28.2

Cash (31-Mar-2021)

14.4m

EV

948.7m
Intersect ENT's current market capitalization is $945 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

108.5m109.1m80.6m

Revenue growth, %

13%1%(26%)

Cost of goods sold

22.6m21.8m30.3m

Gross profit

85.9m87.4m50.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

26.7m26.7m24.1m19.8m9.8m22.7m24.3m27.3m

Cost of goods sold

4.6m5.0m4.9m6.4m7.4m7.8m8.5m8.3m

Gross profit

22.0m21.6m19.2m13.4m2.4m14.9m15.9m19.0m

Gross profit Margin, %

83%81%80%68%25%65%65%70%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

13.4m34.8m9.9m19.8m9.5m20.7m13.5m

Accounts Receivable

8.3m11.5m14.4m16.6m19.6m19.1m14.6m

Prepaid Expenses

2.9m2.7m2.3m3.5m

Inventories

951.0k1.5m1.3m8.5m11.6m17.0m12.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.4m)(26.6m)(25.2m)(16.4m)(22.9m)(43.0m)(72.3m)

Depreciation and Amortization

1.2m1.5m1.9m2.7m2.8m

Inventories

(541.0k)(544.0k)(1.7m)(2.9m)(2.5m)(5.1m)6.6m

Accounts Payable

645.0k(230.0k)1.2m203.0k2.1m(1.2m)1.5m
USDQ2, 2014

Financial Leverage

-0.2 x
Show all financial metrics

Intersect ENT Operating Metrics

Intersect ENT's Patients was reported to be 150 k in FY, 2016.
FY, 2016

Accounts

2.4 k

Patents (US)

30

Patents Pending

37

Patients

150 k

Intersect ENT Acquisitions / Subsidiaries

Company NameDateDeal Size
FiagonSeptember 15, 2020€60 m
Intersect ENT GmbH

Intersect ENT Revenue Breakdown

Embed Graph

Intersect ENT revenue breakdown by business segment: 92.3% from PROPEL family of products, 6.6% from SINUVA and 1.1% from Other

Human Capital Metrics

Embed Graph

Intersect ENT Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Intersect ENT Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Intersect ENT Online and Social Media Presence

Embed Graph

Intersect ENT Company Culture

  • Overall Culture

    C-

    65/100

  • CEO Rating

    B

    70/100

  • Compensation

    B-

    72/100

Learn more on Comparably

Intersect ENT Blogs

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL ® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist,

Intersect ENT Reports Third Quarter 2021 Financial Results

MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021 .

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe Content Import Thu, 10/28/2021 - 07:02 First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe Oct …

Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021

Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021 Maricel.Felici… Tue, 09/14/2021 - 13:06 Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021 Sep 20, 2…

Intersect ENT Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 6, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021 .

U.S. Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 26, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader
Show more

Intersect ENT Frequently Asked Questions

  • When was Intersect ENT founded?

    Intersect ENT was founded in 2003.

  • Who are Intersect ENT key executives?

    Intersect ENT's key executives are Thomas A. West, Patrick Broderick and Reyna Fernandez.

  • How many employees does Intersect ENT have?

    Intersect ENT has 406 employees.

  • What is Intersect ENT revenue?

    Latest Intersect ENT annual revenue is $80.6 m.

  • What is Intersect ENT revenue per employee?

    Latest Intersect ENT revenue per employee is $198.4 k.

  • Who are Intersect ENT competitors?

    Competitors of Intersect ENT include Stryker, Lyra Therapeutics and Regeneron Pharmaceuticals.

  • Where is Intersect ENT headquarters?

    Intersect ENT headquarters is located at 1555 Adams Dr, Menlo Park.

  • Where are Intersect ENT offices?

    Intersect ENT has an office in Menlo Park.

  • How many offices does Intersect ENT have?

    Intersect ENT has 1 office.